A glucose monitor that can be monitored remotely from another room and is intended for use with a specific insulin pump has been approved by the Food and Drug Administration, the manufacturer, Medtronic, has announced.
A press release issued by the company said that the glucose monitor enables parents or caregivers to monitor the status of an individual's insulin pump and glucose trends, with alerts and alarms that can alert them at their bedside if, for example, the glucose levels of a child or adult sleeping in another room are dropping in the middle of the night.
The device is being marketed as the “mySentry Remote Glucose Monitor,” and is used with the MiniMed Paradigm Real-Time Revel System, an insulin pump with a continuous glucose monitor, the Medtronic statement said. At press time, there was no notice of the approval on the FDA's website.